Implementing protocol-based therapy of continuous neuromuscular blockade provides cost minimization

Journal of Pharmacy Technology

Volumn 17, Issue 2, 2001, Pages 49-55

  MacLaren, R ^a   Toombs, L K ^a   Plamondon, J M ^a   Rocker, G M ^a   Patrick, W D ^a   Hall, R I ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; VECURONIUM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DRUG COST; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LENGTH OF STAY; MALE; NEUROMUSCULAR BLOCKING; PARALYSIS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL;

EID: 0035048582     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250101700204     Document Type: Article

References (29)

1. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey
2. Sedatives, analgesics, and paralytics in the ICU
3. Use of sedatives, analgesics, and neuromuscular blocking agents in Danish ICUs 1996/97. A national survey
4. Postal survey on the long-term use of neuromuscular block in the intensive care unit
5. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants
6. Practice parameters for sustained neuromuscular blockade in the adult critically ill patient: An executive summary
7. A retrospective analysis of long-term use of nondepolarizing neuromuscular blocking agents in the intensive care unit, and guidelines for drug selection
8. The impact of practice guidelines on prescribing patterns of nondepolarizing neuromuscular blocking agents
9. The clinical and economic impact of the implementation of a neuromuscular blocking agent protocol
10. Development of algorithms for treating patients in the intensive care unit
11. A prospective evaluation of empiric vs. protocol-based continuous sedation in critically ill patients
12. Controlled sedation with alphalaxone-alphadolone
13. Cost-effective reduction of neuromuscular-blocking drug expenditures
14. Neuromuscular blocking effects and train-of-four fade with cisatracurium: Comparison with other nondepolarising relaxants
15. Do shorter-acting neuromuscular blocking drugs or opioids associate with reduced intensive care unit or hospital lengths of stay after coronary artery bypass grafting? CABG clinical bench-marking database participants
16. Continuous infusions of atracurium and vecuronium, compared with intermittent boluses of pancuronium: Dose requirements and reversal
17. The level of neuromuscular block needed to suppress diaphragmatic movement during tracheal suction in patients with raised intracranial pressure: A study with vecuronium and atracurium
18. Comparison of the neuromuscular recovery after paralysis with atracurium versus vecuronium in an ICU patient with renal insufficiency
19. Paralysis in the critically ill: Intermittent bolus pancuronium compared with continuous infusion
20. Vecuronium infusions for prolonged muscle relaxation in the intensive care unit
21. A double-blind comparison of vecuronium administered by the Springfusor infusion device to vecuronium by intermittent bolus injection in critically ill adult patients
22. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit
23. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients
24. Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients
25. Peripheral nerve stimulator use in critically ill patients
26. Prediction of creatinine clearance from serum creatinine
27. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit
28. Neuromuscular blockade in the intensive care unit
29. A pharmacoeconomic analysis of neuromuscular blocking agents in the operating room